Paradox Immunotherapeutics is BIO’s emerging Start-Up Stadium winner

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Paradox Immunotherapeutics, a biotech company based in Toronto, has been announced the winner of Biotechnology Innovation Organization’s (BIO) 2023 Start-Up Stadium! Paradox is focused on the development of monoclonal antibody (mAb) therapies for the treatment of protein misfolding diseases, including amyloidosis. 

Congratulations to Paradox and to all the finalists! We are proud to share that Paradox is an OBIO® member and an alumnus of our BDSP™, CAAP®, H2BB™ and WiHI programs.

Arsheen Kaur
Previous

Zucara Therapeutics doses first patient in Phase 2a ‘ZONE’ trial
Next

Ontario Brain Institute announces $600,000 in funding to the NERVE cohort